- Home
- ORIS vs NXL Comparison
ORIS vs NXL Comparison
Compare ORIS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIS
- NXL
- Stock Information
- Founded
- ORIS 2014
- NXL 2010
- Country
- ORIS China
- NXL United States
- Employees
- ORIS N/A
- NXL N/A
- Industry
- ORIS Farming/Seeds/Milling
- NXL Medical Specialities
- Sector
- ORIS Consumer Staples
- NXL Health Care
- Exchange
- ORIS Nasdaq
- NXL Nasdaq
- Market Cap
- ORIS 19.5M
- NXL 21.0M
- IPO Year
- ORIS 2024
- NXL 2022
- Fundamental
- Price
- ORIS $0.55
- NXL $0.92
- Analyst Decision
- ORIS
- NXL Strong Buy
- Analyst Count
- ORIS 0
- NXL 1
- Target Price
- ORIS N/A
- NXL $5.00
- AVG Volume (30 Days)
- ORIS 148.3K
- NXL 89.7K
- Earning Date
- ORIS 02-21-2025
- NXL 08-07-2025
- Dividend Yield
- ORIS N/A
- NXL N/A
- EPS Growth
- ORIS N/A
- NXL N/A
- EPS
- ORIS 0.17
- NXL N/A
- Revenue
- ORIS $15,014,000.00
- NXL $131,065.00
- Revenue This Year
- ORIS N/A
- NXL $79.59
- Revenue Next Year
- ORIS N/A
- NXL $334.65
- P/E Ratio
- ORIS $3.26
- NXL N/A
- Revenue Growth
- ORIS N/A
- NXL N/A
- 52 Week Low
- ORIS $0.51
- NXL $0.59
- 52 Week High
- ORIS $56.01
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- ORIS N/A
- NXL 28.61
- Support Level
- ORIS N/A
- NXL $1.12
- Resistance Level
- ORIS N/A
- NXL $1.12
- Average True Range (ATR)
- ORIS 0.00
- NXL 0.09
- MACD
- ORIS 0.00
- NXL -0.01
- Stochastic Oscillator
- ORIS 0.00
- NXL 20.91
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.